Discontinuation of imatinib mesylate could improve renal impairment in chronic myeloid leukemia
We aim to report a CML case that had fluid retention and serum creatinine increase under long-term imatinib mesylate (IM) treatment. A 68-year-old woman was diagnosed with chronic myeloid leukemia, and IM was started in 2002 with a dose of 400 mg/day. She had achieved complete hematological, molecul...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
De Gruyter
2018-12-01
|
| Series: | Open Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1515/med-2019-0004 |